Darrel P. Cohen was named chief medical officer of cell therapy at Athenex Inc. In this role, Cohen will lead the company’s clinical development, clinical operations, and regulatory affairs functions, replacing Kurt Gunter.
Ipsen and Sutro Biopharma formed an exclusive global licensing agreement for STRO-003, an antibody-drug conjugate in the final stages of preclinical development which targets the ROR1 tumor antigen which is known to be overexpressed in many different cancer types including solid tumors and hematological malignancies.
